论文部分内容阅读
目的:评价白蛋白静注在新生儿黄疸中的应用价值以及安全性。方法:研究选择我院收治的新生儿黄疸80例,患儿均于2015年1月份到2016年10月份入院治疗。随机性分组,对照组予以常规治疗,共40例;实验组同时静注白蛋白,共40例;观察两组患儿的治疗情况,并予以比较。结果:在总有效率方面,实验组为95%(38/40),对照组为77.5%(31/40),实验组比对照组高,组间数据差异性明显且统计学意义成立,P<0.05;在TBIL、DBIL以及IBIL方面,治疗后患者上述指标均下降,且实验组的降幅比对照组大,组间数据差异性明显且统计学意义成立,P<0.05;两组患儿不良反应均轻微。结论:应用白蛋白静注对新生儿黄疸进行治疗,能够有效降低患儿的胆红素,且安全性高,值得推荐。
Objective: To evaluate the value and safety of intravenous albumin in neonatal jaundice. Methods: 80 cases of neonatal jaundice admitted to our hospital were studied. All patients were admitted to hospital from January 2015 to October 2016. Random group, the control group to be routine treatment, a total of 40 cases; experimental group also intravenous albumin, a total of 40 cases; treatment of children in both groups were observed and compared. Results: In the total effective rate, the experimental group was 95% (38/40), the control group was 77.5% (31/40), the experimental group was higher than the control group, the difference between the groups was significant and the statistical significance was established, P <0.05; in the patients with TBIL, DBIL and IBIL, the above indicators of patients after treatment decreased, and the decline in the experimental group larger than the control group, significant differences between the groups of data and statistical significance, P <0.05; two groups of children with bad The reaction is mild. Conclusion: The treatment of neonatal jaundice with albumin intravenous injection can effectively reduce the children’s bilirubin, and high safety, it is recommended.